Douglas J. MacMaster Jr., a retired senior vice president ofMerck & Co. Inc. and an Escagenetics Corp. director,.was namedchairman and chief executive of PhytoPharmaceuticals Inc., anew subsidiary of Escagenetics. Raymond J. Moshy,Escagenetics' chief executive officer, was appointed aPhytoPharmaceuticals director and chairman of its executivecommittee. Others named as directors of the new companyinclude A.M. MacKinnon, former president of Ciba-Geigy Corp.,William J. Koenig, Escagenetics' chief financial officer, andWilliam R. Sharp, who was recruited last February asEscagenetics' vice president for pharmaceuticals, primarily tohead the PhytoPharmaceuticals division.

Christine Jacobs was named president and chief operatingofficer of Theragenics Corp., a cancer therapy company based inAtlanta. John V. Herndon will remain chairman and chiefexecutive officer. Jacobs, who has been vice president ofgeneral sales and marketing, will also fill the position ofdirector vacated by Bruce Smith, who will remain secretary,treasurer and chief financial officer.

Liposome Technology Inc. named Peter V. Leigh vice presidentand chief financial officer. He was corporate controller of Bio-Rad Laboratories. LTI of Menlo Park, Calif., is developingliposome and lipid-based pharmaceuticals.

PerSeptive Biosystems Inc. named Robert S. Fein vice presidentand chief financial officer and Robert B. Anacone vice presidentof marketing and sales. Fein was director of corporate strategyfor Thermo Electron Corp.. Anacone was vice president ofworldwide marketing and sales for Serono Diagnostics Inc.Cambridge, Mass.-based PerSeptive designs, manufactures andmarkets proprietary products and systems for purifying andanalyzing biomolecules.

(c) 1997 American Health Consultants. All rights reserved.